Navigation Links
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Date:6/19/2009

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

"We are disappointed that this study with lestaurtinib did not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for life-threatening diseases," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon.

The results of this study in relapsed AML will be submitted for presentation at a future medical meeting. The outcome of this study has no impact on the company's previously issued financial guidance for 2009.

"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like Cephalon to make that investment and take that risk if we are to improve patient outcomes and the overall cost of healthcare."

Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
2. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
3. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
9. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
10. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
11. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... Kan. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Trust Alliance (HITRUST) under its Common Security Framework ... Enterprise Security and Privacy Manager, "We appreciate this ... level of commitment that this certification signifies. Our ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s ...
(Date:8/21/2014)... , Aug. 21, 2014  ACI Clinical ... for independent Data Monitoring Committees. Using ... 30 percent over industry standard costs and receive ... industry leader in committee services. Leveraging ... recruitment and contracting, charter development, statistical programming and ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... statement was issued today by the law firm of Barroway ... hereby given that a class action lawsuit was filed in ... California on behalf of purchasers of the securities of SciClone ... "Company"), who purchased or otherwise acquired SciClone,s securities between May ...
... NVAX ) President and CEO Dr. Rahul Singhvi today ... Secretary Kathleen Sebelius and other public health officials announcing a ... vaccines to prevent the spread of infectious diseases and issued ... initiatives: Define and strengthen FDA regulatory processes ...
Cached Medicine Technology:Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 3NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:8/22/2014)... August 22, 2014 Millennium Treatment ... in Lantana, FL, recently launched a new website. ... for information can now find Millennium Treatment Group ... just went live at the beginning of July. ... facility can be found on the website. There’s ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Beat ... how they can use natural methods to completely cure ... caught the attention of Shane Michaels, prompting an investigative ... that affects the skin, it can still be extremely ... reports Michaels. “The intense itching and pain that it ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
(Date:8/22/2014)... factor receptor (EGFR) mutations found in the circulating free ... cell lung cancer (NSCLC) patients correlates well with the ... tyrosine kinase inhibitor (TKI) therapy is approved for EGFR ... standard for determining mutation status is with DNA derived ... not available. A more abundant and less invasive source ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
... SAN JOSE, Calif., Sept. 2 MAQUET Cardiovascular ... complaint filed by Terumo,Cardiovascular Systems Corp. (Terumo CSC) ... District of California. The complaint alleges that,MAQUET,s VASOVIEW ... In April 2008, MAQUET filed patent infringement ...
... SANTA YNEZ VALLEY, Calif., Sept. 2 Platinum Performance,client McLain ... Summer Olympics in Beijing, China, on August 19, as "probably ... sport.", Winning the first ever jump-off in Olympic Games ... the Team Show Jumping title at the Hong Kong,Olympic Equestrian ...
... Sept. 2 MBF Healthcare,Acquisition Corp. (Amex: ... purpose,acquisition company, announced today the amendment of ... of Critical Homecare Solutions,Holdings, Inc. ("CHS"), based ... February 6, 2008 (the "Stock Purchase Agreement"). ...
... 2 Herley Industries,Inc. (Nasdaq: HRLY ), a ... solutions for the defense, aerospace and medical,industries worldwide, announced ... Jefferies & Company, Inc., as its financial,advisor to assist ... Myron Levy, Chairman and CEO, said, "We are pleased ...
... Help Payers and Providers Contain Costs and ... Improve Patient Outcomes Together, ... of Innovent Oncology, a service division that offers a first-time,opportunity ... designed specifically for the complexity of cancer,care. With a unique ...
... showed benefits even a year after routine was stopped, ... -- Exercise may help treat memory problems in adults, ... focused on 138 people age 50 and older at ... activity program led to modest improvements in cognitive function ...
Cached Medicine News:Health News:MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems 2Health News:Platinum Performance Clients Take Home Medals for the USA 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives 2Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Exercise May Help Prevent Age-Related Memory Loss 2
... Slit Lamp features easy-to-use controls to help ... to a halogen bulb that gives up ... with powers of 10X and 16X, the ... accepts commercially available C-mount cameras, allowing physicians ...
... uses state-of-the-art waveform analysis and ... a 65MHz rate to obtain ... and averages nine measurements and ... fits comfortably into the hand ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Medicine Products: